Kardigan, Inc. (NASDAQ:KARD) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Kardigan, Inc. (NASDAQ:KARD – Get Free Report) have been given a consensus rating of “Moderate Buy” by the ten research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $41.00.

Several brokerages recently commented on KARD. Wall Street Zen downgraded Kardigan from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Robert W. Baird initiated coverage on Kardigan in a research note on Wednesday, October 21st. They issued an “outperform” rating and a $43.00 target price for the company. HC Wainwright started coverage on Kardigan in a research note on Wednesday, November 4th. They issued a “buy” rating and a $42.00 target price for the company. UBS Group initiated coverage on Kardigan in a report on Monday, October 12th. They issued a “buy” rating and a $25.00 price target for the company. Finally, Weiss Ratings lowered Kardigan from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, November 10th.

Check Out Our Latest Stock Report on KARD

Kardigan Trading Down 6.6%

Shares of NASDAQ KARD opened at $12.32 on Thursday. The stock’s fifty day moving average price is $14.67. The company has a market capitalization of $1.15 billion and a PE ratio of -4.28. Kardigan has a twelve month low of $12.23 and a twelve month high of $27.00.

Kardigan (NASDAQ:KARD – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.16. As a group, analysts forecast that Kardigan will post -3.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Kardigan

Several institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. bought a new stake in Kardigan during the 3rd quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. acquired a new stake in Kardigan during the 3rd quarter worth approximately $47,000. Legal & General Group Plc bought a new position in Kardigan in the second quarter valued at approximately $119,000. New York State Common Retirement Fund bought a new position in Kardigan in the third quarter valued at approximately $145,000. Finally, Squarepoint Ops LLC bought a new position in Kardigan in the second quarter valued at approximately $247,000.

Kardigan Company Profile

(Get Free Report)

Kardigan is a biopharmaceutical company focused on developing medicines for cardiovascular diseases. Its work centers on advancing therapeutic candidates intended to address heart and vascular conditions. The company’s activities include research and development of a pipeline of cardiovascular drug candidates. Kardigan was launched as a biotechnology company in 2024; detailed information about its commercial products and geographic operations is limited.

See Also

Analyst Recommendations for Kardigan (NASDAQ:KARD)

Receive News & Ratings for Kardigan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kardigan and related companies with MarketBeat.com's FREE daily email newsletter.